2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperlipoproteinemia Type I: new trials by email Literature Review of Hyperlipoproteinemia Type I trials Research Report on Hyperlipoproteinemia Type I
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) ARO-APOC3, sterile normal saline (0.9% NaCl) - Hypertriglyceridemia, Familial Chylomicronemia | Phase 1 | Completed | Arrowhead Pharmaceuticals | 112 | 2019-03-08 | 2025-12-24 |
| Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia LCQ908, Placebo - Hyperlipoproteinemia | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 8 | 2010-05-01 | 2020-12-17 |
Hypertriglyceridemia (2) · Hyperlipoproteinemias (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dyslipidemias (2) · Genetic Diseases, Inborn (2) · Hyperlipidemias (2) · Lipid Metabolism Disorders (2) · Lipid Metabolism, Inborn Errors (2) · Metabolic Diseases (2) · Metabolism, Inborn Errors (2) · Nutritional and Metabolic Diseases (2) · Hyperlipoproteinemias (1)
pradigastat (1)
Arrowhead Pharmaceuticals (1) · Novartis Pharmaceuticals (1)
Canada (2) · Australia (1) · New Zealand (1)